Demonstrates Prolonged Progression Free Survival of Two Patients in Acclaim-1 and Partial Remission from Maintenance Therapy in Acclaim-3Re-focuses Oncology Clinical Development Program and Advances Work to Establish Biomarkers to Enrich Clinical Trial Patient PopulationsAUSTIN, Texas, Aug. 14, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announc ...